Verdence Capital Advisors’s Marker Therapeutics MRKR Stock Holding History

Verdence Capital Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,844	Closed	-$18K	–	528
2021 Q4	$18K	Buy	+1,844	New	+$24.5K	﹤0.01%	504

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

Verdence Capital Advisors's MRKR Position: Q1 2022 in Review

Verdence Capital Advisors sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 1,844 shares — an estimated $18K sold.

Verdence Capital Advisors first reported a position in MRKR in Q4 2021 and held it in 1 quarter. The position peaked at $18K in Q4 2021. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

Verdence Capital Advisors reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
Verdence Capital Advisors sold 1,844 Marker Therapeutics shares in Q1 2022, an estimated $18K.
Verdence Capital Advisors first reported a position in Marker Therapeutics in Q4 2021 and held it in 1 quarter.
Verdence Capital Advisors's Marker Therapeutics position peaked at $18K in Q4 2021.
49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on Verdence Capital Advisors's 13F filing for Q1 2022, filed 2 May 2022.